A phase I study of ZD 1839 (Iressa) [gefitinib] in combination with irinotecan, leucovorin [folinic acid], and 5-fluorouracil in previously untreated, stage IV colorectal cancer

Trial Profile

A phase I study of ZD 1839 (Iressa) [gefitinib] in combination with irinotecan, leucovorin [folinic acid], and 5-fluorouracil in previously untreated, stage IV colorectal cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs Gefitinib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2007 Status changed from in progress to completed.
    • 15 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top